Green Cross Medical Science Corporation
Green Cross Medical Science Corporation manufactures and sells diagnostic reagents and medical devices in South Korea and internationally. The company offers immunology diagnostic reagents. It also provides COVID-19 kit; blood glucose monitoring system; HbA1c test machine; and Gcare LIPID and LIPID printer. Green Cross Medical Science Corporation was founded in 1972 and is headquartered in Yongin… Read more
Green Cross Medical Science Corporation (142280) - Total Assets
Latest total assets as of September 2025: ₩96.65 Billion KRW
Based on the latest financial reports, Green Cross Medical Science Corporation (142280) holds total assets worth ₩96.65 Billion KRW as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Green Cross Medical Science Corporation - Total Assets Trend (2014–2024)
This chart illustrates how Green Cross Medical Science Corporation’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Green Cross Medical Science Corporation - Asset Composition Analysis
Current Asset Composition (December 2024)
Green Cross Medical Science Corporation's total assets of ₩96.65 Billion consist of 44.8% current assets and 55.2% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0.8% |
| Accounts Receivable | ₩17.48 Billion | 19.9% |
| Inventory | ₩18.57 Billion | 21.1% |
| Property, Plant & Equipment | ₩45.05 Billion | 51.2% |
| Intangible Assets | ₩428.07 Million | 0.5% |
| Goodwill | ₩253.75 Million | 0.3% |
Asset Composition Trend (2014–2024)
This chart illustrates how Green Cross Medical Science Corporation's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Green Cross Medical Science Corporation's current assets represent 44.8% of total assets in 2024, a decrease from 76.4% in 2014.
- Cash Position: Cash and equivalents constituted 0.8% of total assets in 2024, up from 0.6% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 1.0% in 2014.
- Asset Diversification: The largest asset category is property, plant & equipment at 51.2% of total assets.
Green Cross Medical Science Corporation Competitors by Total Assets
Key competitors of Green Cross Medical Science Corporation based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Green Cross Medical Science Corporation - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - Green Cross Medical Science Corporation generates 1.18x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, Green Cross Medical Science Corporation generates $ 4.07 in net profit.
Green Cross Medical Science Corporation - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.11 | 1.02 | 1.57 |
| Quick Ratio | 0.68 | 0.60 | 0.93 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₩4.72 Billion | ₩ 914.43 Million | ₩ 22.39 Billion |
Green Cross Medical Science Corporation - Advanced Valuation Insights
This section examines the relationship between Green Cross Medical Science Corporation's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.71 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -2.8% |
| Total Assets | ₩87.97 Billion |
| Market Capitalization | $25.64 Million USD |
Valuation Analysis
Below Book Valuation: The market values Green Cross Medical Science Corporation's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Green Cross Medical Science Corporation's assets decreased by 2.8% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Green Cross Medical Science Corporation (2014–2024)
The table below shows the annual total assets of Green Cross Medical Science Corporation from 2014 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩87.97 Billion | -2.82% |
| 2023-12-31 | ₩90.53 Billion | -6.16% |
| 2022-12-31 | ₩96.47 Billion | +0.88% |
| 2021-12-31 | ₩95.63 Billion | -9.44% |
| 2020-12-31 | ₩105.60 Billion | +18.83% |
| 2019-12-31 | ₩88.87 Billion | +38.91% |
| 2018-12-31 | ₩63.97 Billion | +5.67% |
| 2017-12-31 | ₩60.54 Billion | -4.81% |
| 2016-12-31 | ₩63.61 Billion | -12.40% |
| 2015-12-31 | ₩72.61 Billion | +39.37% |
| 2014-12-31 | ₩52.10 Billion | -- |